
First clinical data for allogeneic CAR-T in autoimmune disease
Allogene Therapeutics has reported preliminary safety, efficacy and translational data from the ongoing Phase I RESOLUTION study evaluating ALLO-329, an investigational, off-the-shelf allogeneic CAR-T product designed specifically for autoimmune disease. The data were presented at the American College of Rheumatology (ACR) Convergence in Orlando, Florida. … Read More





